NASDAQ:DMAC - DiaMedica Therapeutics Stock Price, News, & Analysis

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics Inc (NASDAQ:DMAC) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. View DiaMedica Therapeutics' Earnings History.

DiaMedica Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, September 4th 2019. View Earnings Estimates for DiaMedica Therapeutics.

3 brokers have issued 1-year target prices for DiaMedica Therapeutics' stock. Their predictions range from $8.00 to $9.00. On average, they anticipate DiaMedica Therapeutics' share price to reach $8.50 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price. View Analyst Price Targets for DiaMedica Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DiaMedica Therapeutics.

News headlines about DMAC stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DiaMedica Therapeutics earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for DiaMedica Therapeutics.

DiaMedica Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 15,900 shares, an increase of 87.1% from the April 30th total of 8,500 shares. Based on an average daily volume of 46,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company's stock are short sold. View DiaMedica Therapeutics' Current Options Chain.

Some companies that are related to DiaMedica Therapeutics include Chimerix (CMRX), Nature's Sunshine Products (NATR), Acer Therapeutics (ACER), LifeVantage (LFVN), Galectin Therapeutics (GALT), TAIWAN LIPOSOME/S (TLC), BioXcel Therapeutics (BTAI), Strongbridge Biopharma (SBBP), CytoDyn (CYDY), Minerva Neurosciences (NERV), Kezar Life Sciences (KZR), Millendo Therapeutics (MLND), Newron Pharmaceuticals (NWPHF), Sol Gel Technologies (SLGL) and Osmotica Pharmaceuticals (OSMT).

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include PentaNova Energy (PNO), Auryn Resources (AUG), Avcorp Industries (AVP), Aptose Biosciences (APTO), Adamis Pharmaceuticals (ADMP), Arcturus Therapeutics (ARCT), Aurinia Pharmaceuticals (AUPH), Capricor Therapeutics (CAPR), Cray (CRAY) and Inovio Pharmaceuticals (INO).

(DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

DiaMedica Therapeutics' lock-up period expired on Wednesday, June 5th. DiaMedica Therapeutics had issued 4,100,000 shares in its public offering on December 7th. The total size of the offering was $16,400,000 based on an initial share price of $4.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DMAC stock can currently be purchased for approximately $3.82.

DiaMedica Therapeutics has a market capitalization of $45.67 million and generates $500,000.00 in revenue each year. DiaMedica Therapeutics employs 9 workers across the globe.View Additional Information About DiaMedica Therapeutics.

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]